文档介绍：埃克替尼对比厄洛替尼联合放疗治疗老年EGFR突变型Ⅲ期肺腺癌患者的临床分析
该论文来源于网络，本站转载的论文均是优质论文，供学习和研究使用，文中立场与本网站无关，版权和著作权归原作者所有，如有不愿意被转载的情况，请通知我们删除已转载的信息，如果需要分享，请保留本段说明。
[摘要] 目的 比较埃克替尼与厄洛替尼分别联合放疗治疗老年Ⅲ期肺腺癌的临床疗效和安全性。方法 研究对象为方便选取该院2012年10月—2017年12月治疗的120例老年Ⅲ期肺腺癌患者，随机将所有研究对象分为两组，分别为埃克替尼组及厄洛替尼组，每组60例，评估两组患者的临床疗效及不良反应发生情况。结果 %，%，中位PFS （±）个月，%，%，中位PFS （±）个月，两组比较差异有统计学意义（χ2=，χ2=，t=，P<）；埃克替尼与厄洛替尼组的不良反应，主要表现为皮疹、腹泻、ALT和（或）AST升高等，两组比较差异无统计学意义（P>）。结论 埃克替尼联合放疗治疗老年Ⅲ期肺腺癌的临床疗效显著高于厄洛替尼联合放疗，同时埃克替尼联合放疗与厄洛替尼联合放疗不良反应相似。
[关键词] 埃克替尼；厄洛替尼；老年Ⅲ期肺腺癌
[中图分类号] R734 [文献标识码] A [文章编号] 1674-0742（2019）03（c）-0114-03
[Abstract] Objective To compare the clinical efficacy and safety of Icotinib hydrochloride and pemetrexed in the treatment of old-age type III lung adenocarcinoma. Methods Convenient select 120 patients with advanced lung adenocarcinoma who were treated in hospital from October 2012 to Dceember 2017 were randomly divided into two groups， the Icotinib group and Erlotinib group. Results The effective ORR of the ectatinib group was %， the disease control rate was %， the median PFS was （±） months， the erlotinib group had an effective ORR of %， and the disease control rate was %. The median PFS was （±）months， and the difference between the two groups was statistically significant （χ2=， χ2=， t=， P<）. The adverse reactions of ectinib and erlotinib group were mainly manifested for rash， diarrhea， ALT and/or AST elevation， there was no significant difference between the two groups （P>）. Conclusion The clinical efficacy of Icotinib combined with cisplatin in the treatment of EGFR mutant stage III lung adenocarcinoma is significantly higher than that of Erlotinib plus cisplatin. Icotinib combined with cisplatin is not compatible with Erlotinib plus cisplatin， which is less reaction and higher safety.
[Key word